Verrica Pharmaceuticals Inc.

VRCA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001660334


None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $47.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, thin data; fortress balance sh... not computable: distress
Inputs computable	6 of 14
Graded from	filings received through Mar 11, 2026 241 days before the rescan; latest periodic filing 10-Q received Aug 6, 2026
Last close	$3.25 2026-11-06; market equity $55.8M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 11, 2026

We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Our commercial product, YCANTH (VP-102), was approved by the U.S.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 80.1						
Gross profitability	not computable	32.3%				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(0.5%)	(6.6%)	80.1	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 67.2					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(19.42)	(0.37)	73.1	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.59x	2.94x	61.3	828	2025-12-31
Growth and financing, sleeve percentile 46.9					
Revenue growth, three-year compound	57.9%	10.0%	11.4	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	1.8%	2.2%	48.2	696	2025-12-31
Net share issuance, one year	87.2%	2.5%	80.9	630	2026-03-02

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 87.2%
Thin data	6 of 14 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 30,147,000 USD; Altman Z is not used

What the price implies

at the 2026-11-06 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	32.8%	(2.1%)	71
Distance from 52-week high	(64.9%)	(30.5%)	16
EBIT to enterprise value	(27.9%)	(1.5%)	22
Free cash flow yield	(32.2%)	(1.0%)	18
Book value to price	0.08	0.29	22
Sales to price	0.65	0.30	73
Composite equity issuance, five years	191.0%	21.4%	88
Relative strength against the sector, log excess return	0.12	(0.19)	71

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$11.2M
Operating cash flow, four quarters	-$13.3M
Months of runway	10.1
Days since last periodic filing	93 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	$219,412

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$7.6M	2024-12-31	2025-03-11	10-K	25-037172
2	cost of revenue	us-gaap:CostOfRevenue	$2.6M	2024-12-31	2025-03-11	10-K	25-037172
3	assets	us-gaap:Assets	$54.1M	2024-12-31	2026-03-11	10-K	26-000008
4	net income	us-gaap:NetIncomeLoss	-$17.9M	2025-12-31	2026-03-11	10-K	26-000008
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$17.6M	2025-12-31	2026-03-11	10-K	26-000008
6	assets	us-gaap:Assets	$47.1M	2025-12-31	2026-03-11	10-K	26-000008
7	current assets	us-gaap:AssetsCurrent	$42.5M	2025-12-31	2026-03-11	10-K	26-000008
8	current liabilities	us-gaap:LiabilitiesCurrent	$16.4M	2025-12-31	2026-03-11	10-K	26-000008
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$324.9M	2025-12-31	2026-03-11	10-K	26-000008
10	operating income	us-gaap:OperatingIncomeLoss	-$12.2M	2025-12-31	2026-03-11	10-K	26-000008
11	book equity	us-gaap:StockholdersEquity	$24.7M	2025-12-31	2026-03-11	10-K	26-000008
12	liabilities	us-gaap:Liabilities	$22.4M	2025-12-31	2026-03-11	10-K	26-000008
13	total debt	us-gaap:LongTermDebt	$0	2025-12-31	2026-03-11	10-K	26-000008
14	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$30.1M	2025-12-31	2026-03-11	10-K	26-000008
15	depreciation amortization	us-gaap:Depreciation	$133,000	2025-12-31	2026-03-11	10-K	26-000008
16	operating income	us-gaap:OperatingIncomeLoss	-$65.8M	2023-12-31	2025-03-11	10-K	25-037172
17	interest expense	us-gaap:InterestExpense	$4.0M	2023-12-31	2024-02-29	10-K	24-022659
18	revenue	us-gaap:Revenues	$35.6M	2025-12-31	2026-03-11	10-K	26-000008
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5.1M	2023-12-31	2025-03-11	10-K	25-037172
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.0M	2022-12-31	2024-02-29	10-K	24-022659
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2025-12-31	2026-03-11	10-K	26-000008
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$60.9M	2024-12-31	2026-03-11	10-K	26-000008
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$27,000	2024-12-31	2026-03-11	10-K	26-000008
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$38.6M	2023-12-31	2025-03-11	10-K	25-037172
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$362,000	2023-12-31	2025-03-11	10-K	25-037172
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.6M	2022-12-31	2024-02-29	10-K	24-022659
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$302,000	2022-12-31	2024-02-29	10-K	24-022659
28	assets	us-gaap:Assets	$81.6M	2023-12-31	2025-03-11	10-K	25-037172
29	assets	us-gaap:Assets	$44.7M	2022-12-31	2024-02-29	10-K	24-022659
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	17,178,786	2026-03-02	2026-03-11	10-K	26-000008
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	91,779,993	2025-03-05	2025-03-11	10-K	25-037172

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.